Abstract

Objective- The studies have been shown that aspirin, an anti-inflammatory agent, could reduce occurrence of different cancers. The aim of the present study was to evaluate pharmacological effective concentrations of aspirin with/without radiotherapy on growth rate of MCF-7 breast cancer cell line Design- Experimental Study Animals- The MCF-7 breast cancer cell line from rats Procedures- The MCF-7 breast cancer cell line was prepared commercially and cultured. The cultured cells were then separated to labelled tubes and treated for 24 hours with 1, 2, 3, 4, and 5 mg aspirin plus 0.1 mg doxorubicin. Cells were then exposed to radiation. Cell proliferation and survival were measured by MTT assay, following acridine orange and propidium iodide staining methods using spectrophotometry and fluorescence microscopy. Results- The findings showed that proliferation and survival of the cells treated with 5 mM aspirin followed by radiotherapy were significantly decreased compared to them of the control group (P<0.05). Conclusion and Clinical Relevance- Although anti-proliferative activity of aspirin was lower than that of doxorubicin, it can be considered in combination therapy because of its affordability and cost-effectiveness

Authors and Affiliations